KRAS proto-oncogene, which is mutated in approximately 32–40% of CRC tumors [33,109], has been described as an early event in the development of CRC [109] in which the GTPase activity of KRAS is disabled and downstream signaling is inoperative. The gene discussed is KRAS; the disease is colorectal carcinoma.